Promoter methylated microRNAs: Potential therapeutic targets in gastric cancer (Review)
Authors:
Open Access
- 27 October 2014
- journal article
- review article
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 11 (2) , 759-765
Abstract
Gastric cancer (GC) is the fourth most commonly diagnosed type of cancer worldwide and has the second highest mortality rate of all cancer types. Classical genetics alone does not fully explain how GC occurs; however, epigenetics provides a partial explanation with regard to the cause of cancer. DNA methylation, the best-known type of epigenetic marker, represses the expression of tumor-suppressor genes and is involved in the pathogenesis of various types of human cancer, including GC. Micro (mi)RNAs are critical in the initiation, progression, metastasis and invasion of GC through gene regulation. The dysregulation of miRNAs is widely recognized as a hallmark of cancer. Recently, studies concerning DNA methylation of miRNAs in GC have been frequently reported, and these studies deepen the knowledge of how epigenetic regulation of miRNAs results in GC pathogenesis and indicate novel therapeutic strategies for GC. The present review provides an overview of the reported DNA methylation of miRNAs in GC.Keywords
This publication has 69 references indexed in Scilit:
- Cancer EpigeneticsCA: A Cancer Journal for Clinicians, 2010
- Methylation-associated silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic field defectCarcinogenesis, 2010
- Epigenetic regulation of miR‐196b expression in gastric cancerGenes, Chromosomes and Cancer, 2010
- miR‐181b modulates multidrug resistance by targeting BCL2 in human cancer cell linesInternational Journal of Cancer, 2010
- Comprehensive analysis of CpG islands in human chromosomes 21 and 22Proceedings of the National Academy of Sciences, 2002
- DNA methylation patterns and epigenetic memoryGenes & Development, 2002
- Global and Gene-Specific Methylation Patterns in Cancer: Aspects of Tumor Biology and Clinical PotentialMolecular Genetics and Metabolism, 2002
- Two genetic hits (more or less) to cancerNature Reviews Cancer, 2001
- Aberrant CpG-island methylation has non-random and tumour-type–specific patternsNature Genetics, 2000
- DNA Methyltransferases Dnmt3a and Dnmt3b Are Essential for De Novo Methylation and Mammalian DevelopmentCell, 1999